(Q37868926)

24 August 2017

1 reference

title

Active surveillance for low-risk prostate cancer: an update (English)

1 reference

24 August 2017

1 reference

1

1 reference

24 August 2017

2

Laurence Klotz

1 reference

24 August 2017

language of work or name

English

0 references

publication date

26 April 2011

1 reference

24 August 2017

published in

Nature Reviews Urology

1 reference

24 August 2017

volume

8

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

312-320

1 reference

Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Image guided photothermal focal therapy for localized prostate cancer: phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Careful Selection and Close Monitoring of Low-Risk Prostate Cancer Patients on Active Surveillance Minimizes the Need for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Active surveillance for favorable-risk prostate cancer: who, how and why?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

The role of biopsy core number in selecting prostate cancer patients for active surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Image guidance for focal therapy of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

How good is MRI at detecting and characterising cancer within the prostate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

'Prostatic evasive anterior tumours': the role of magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Active surveillance for the management of prostate cancer in a contemporary cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Results of conservative management of clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Active surveillance for early-stage prostate cancer: review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Anxiety and distress during active surveillance for early prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Active surveillance with selective delayed intervention for favorable risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Quality of life after radical prostatectomy or watchful waiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Delayed versus immediate surgical intervention and prostate cancer outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Active surveillance for favorable-risk prostate cancer: a short review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Early outcomes of active surveillance for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

An analysis of men with clinically localized prostate cancer who deferred definitive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Development of a complex intervention improved randomization and informed consent in a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

From Active Surveillance to the Concept of Secondary Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Quality of life and satisfaction with outcome among prostate-cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

EAU guidelines on prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Early prostate cancer--which treatment do men prefer and why?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Active surveillance: is there a need for better risk stratification at the outset?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Nuclear Magnetic Resonance Imaging of the Prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Contrast-enhanced colour Doppler-targeted prostate biopsy: correlation of a subjective blood-flow rating scale with the histopathological outcome of the biopsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Should Pathologists Routinely Report Prostate Tumour Volume? The Prognostic Value of Tumour Volume in Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Impact of 5α-Reductase Inhibitors on Men Followed by Active Surveillance for Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.50

Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

31 March 2020

1 reference

12 December 2020

NCCN clinical practice guidelines in oncology: prostate cancer

1 reference

12 December 2020

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results

1 reference

12 December 2020

Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups.

1 reference

12 December 2020

Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology

1 reference

12 December 2020

Microbubble contrast for radiological imaging: 1. Principles.

1 reference

12 December 2020

Prostate cancer screening "reloaded"

1 reference

12 December 2020

Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience

1 reference

12 December 2020

Nuclear Magnetic Resonance (NMR) Imaging of the Prostate

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2011.50

1 reference

24 August 2017

1 reference